

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

## POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 14, 2019

Reference is made to the circular (the “**Circular**”) of Innovent Biologics, Inc. (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of extraordinary general meeting of the Company (the “**EGM**”) dated May 24, 2019. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

At the EGM held on June 14, 2019, all the proposed resolutions as set out in the Notice were duly passed by way of poll and the poll results were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
(a)	To approve and confirm the conditional grant of options to Dr. De-Chao Michael Yu (“ <b>Dr. Yu</b> ”) (the “ <b>Proposed Option Grant</b> ”) in accordance with the terms of the post-IPO share option scheme adopted by the Company on June 12, 2018 (the “ <b>Post-IPO ESOP</b> ”)	420,020,763 76.92%	126,046,273 23.08%
(b)	To authorise any one or more of the directors of the Company, with the exception of Dr. Yu (the “ <b>Authorised Directors</b> ”), to exercise the powers of the Company to allot and issue the ordinary shares of the Company pursuant to the Proposed Option Grant under the specific mandate granted to the Directors by the shareholders of the Company pursuant to the unanimous written resolutions of all the shareholders dated June 12, 2018 in accordance with the terms of the Post-IPO ESOP	405,774,629 74.31%	140,292,407 25.69%
(c)	To approve and confirm the conditional grant of restricted shares to Dr. Yu (the “ <b>Proposed RS Grant</b> ”) in accordance with the terms of the restricted share plan adopted by the Company on October 15, 2018 (the “ <b>RS Plan</b> ”)	420,020,763 76.92%	126,046,273 23.08%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
(d)	To authorise any one or more of the Authorised Directors to exercise the powers of the Company to allot and issue the ordinary shares of the Company pursuant to the Proposed RS Grant under the specific mandate granted to the Directors by the shareholders of the Company at the extraordinary general meeting of the Company held on October 15, 2018 in accordance with the terms of the RS Plan	405,774,629 74.31%	140,292,407 25.69%

By order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, June 14, 2019

*Notes:*

- (a) As at the date of the EGM, the total number of shares of the Company in issue was 1,155,052,710 shares.
- (b)
  - (i) As at the date of EGM, as notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and excluding any shares of the Company to be issued pursuant to the Proposed Option Grant and the Proposed RS Grant, Dr. Yu is interested in a total of 145,728,230 shares of the Company.
  - (ii) Dr. Yu, his associates and all other core connected persons of the Company, namely Gloria Bingqinzi Yu (as trustee of the Yu Tong Family Irrevocable Trust) and Great Biono Fortune LP were required to and had abstained from voting in favour of the above proposed resolutions numbered a and b in relation to the Proposed Option Grant and transactions contemplated therein at the EGM in accordance with the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).
  - (iii) Dr. Yu and his associates, namely Gloria Bingqinzi Yu (as trustee of the Yu Tong Family Irrevocable Trust) and Great Biono Fortune LP were required to and had abstained from voting on the above proposed resolutions numbered c and d in relation to the Proposed RS Grant and transactions contemplated therein at the EGM in accordance with the Listing Rules.
- (c) Save as disclosed above, there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the EGM as set out in rule 13.40 of the Listing Rules and no shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM. No parties have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.
- (d) Accordingly, the total number of shares of the Company entitling the holders to attend and vote on the resolutions numbered a and b at the EGM was 1,155,052,710 shares; the total number of shares of the Company entitling the holders to attend and vote on the resolutions numbered c and d at the EGM was only 1,009,324,480 shares.
- (e) The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, Mr. Shuyun Chen as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu and Dr. Kaixian Chen as Independent Non-executive Directors.*